We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byGeorgia Southerly
Modified about 1 year ago
© Frommer Lawrence & Haug LLP BIOSIMILARS: ALTERNATIVE REGULATORY PATHWAYS American Conference Institute FOLLOW-ON BIOLOGICS June 22, 2010 Charles J. Raubicheck 745 Fifth Avenue New York, New York 10171 Phone: (212) 588-0800 Fax: (212) 588-0500
© Frommer Lawrence & Haug LLP 1 BIOSIMILARS UNDER HATCH-WAXMAN Section 505(b)(2) Added by Hatch-Waxman Clinical Studies Not Conducted By or For the NDA Applicant and No Right of Reference 505(b)(2) Applicant Can Rely on Clinical Data it Does Not Develop (Innovator’s S/E Data) Section 505(b)(2) Regulatory Approval Pathway
© Frommer Lawrence & Haug LLP 2 HATCH-WAXMAN: 505(b)(2) NDA (cont’d) Types of data for Reliance Published Literature (previous “Paper NDA”) FDA Finding of Safety and Effectiveness for a Drug Approved Under a Full NDA 505(b)(2) Applicant Relies in Part on Innovator’s S/E Data (505(b)(1)), Plus Data the Applicant Itself Generates FDA’s Rationale: Preclude Unnecessary Clinical Studies for What is Already Known About a Drug
© Frommer Lawrence & Haug LLP 3 HATCH-WAXMAN: 505(b)(2) NDA (cont’d) Announcements of 505(b)(2) Approach 1987 Parkman Letter (Modifications When Clinical Data Required) Preambles: 1989 and 1992 ANDA Regulations 1999 Section 505(b)(2) Guidance Guidance – (b)(2) Applies to Changes to Drugs Previously Approved Under a FULL NDA
© Frommer Lawrence & Haug LLP 4 HATCH-WAXMAN: 505(b)(2) NDA (cont’d) Bridging Studies: Usually Several Clinical Trials At Least One Phase II or Phase III Conference with FDA re Protocol Rare: Bioequivalence
© Frommer Lawrence & Haug LLP 5 HATCH-WAXMAN: 505(b)(2) NDA (cont’d) Examples of Types of Changes Active Ingredient Dosage Form Strength Route of Administration Dosing Regimen Combination Product Indication
© Frommer Lawrence & Haug LLP 6 HATCH-WAXMAN: 505(b)(2) NDA (cont’d) Naturally Derived or Recombinant Active Ingredient Change to prior approved Active Ingredient that is Chemically Synthesized or Derived from Another Source Clinical Bridging Studies: Required to Show that Active Ingredient Is the Same As the Active Ingredient in a Drug Covered by an Approved Full NDA Also, (key here):
© Frommer Lawrence & Haug LLP 7 SECTION 505(b)(2) NDA: CHALLENGES Proprietary Data (Clinical and CMC) FDA Only Refers Internally Data Protected: No Public Disclosure Statute Doesn’t Preclude Reliance on Innovator’s S/E Data No Unconstitutional Taking No Expectation of Confidentiality (Highly Regulated Field) REJECTED BY FDA
© Frommer Lawrence & Haug LLP 8 SECTION 505(b)(2) NDA: BIOSIMILARS No Statutory Exclusion Biologic Is a “Drug” Highly Similar Active Ingredient Precedent: Insulin (Historical) Need for Biosimilar Pathway
© Frommer Lawrence & Haug LLP 9 SECTION 505(b)(2) NDA: BIOSIMILARS (cont’d) 2005 – HYLENEX (Recombinant Hyaluronidase): Increases Absorption and Dispersion of Other Injected Drugs Reliance: Amphastar ® (bovine-derived) 2005 – FORTICAL (Recombinant Salmon Calcitonin): Ostoporosis Reliance: Miacalcin ® (Synthetic) Recent 505(b)(2) Approvals
© Frommer Lawrence & Haug LLP 10 SECTION 505(b)(2) NDA: BIOSIMILARS (cont’d) 2006 – OMNITROPE (Recombinant Somatropin): Human Growth Hormone (rhGH) Reliance: Genotropin ® CASE STUDY: OMNITROPE Citizen Petitions (Pfizer, BIO, Genentech) Denied FDA Rationale 505(b)(2): Chemical Structure of Active Ingredient “Highly Similar” (as in Biosimilars Act) (“Sameness” Not Required)
© Frommer Lawrence & Haug LLP 11 SECTION 505(b)(2) NDA: BIOSIMILARS (cont’d) rhGH a Relatively Simple Recombinant Protein (Characterization, Purification) Highly Similar Characteristics: Pharmacokinetic, Pharmacodynamic, Bioavailability Clinical Experience and Published Literature on rhGH Bridging Studies PK/PD Studies Phase III Clinical Trials (4)
© Frommer Lawrence & Haug LLP 12 ANDA APPROVAL VEHICLE ANDA Must Be Filed for: Same Active Ingredient, Dosage Form, Strength, Route of Administration, Indications Drug Product which Differs From Innovative Product in One of the Above Respects, but Has an Approved Suitability Petition Allowing the Change Does Not Require S/E Clinical Studies Can’t Be a 505(b)(2)
© Frommer Lawrence & Haug LLP 13 ANDA APPROVAL VEHICLE (cont’d) Ferring’s REPRONEX (Menotropins) for Infertility Active Ingredient: Follicle-Stimulating Hormone (“FSH”) Citizen Petition Opposition: Serono’s Pergonal ® FSH in REPRONEX Different From FSH in Pergonal ® (Different Isoforms of Hormone) ANDA Route Improper Example
© Frommer Lawrence & Haug LLP 14 ANDA APPROVAL VEHICLE (cont’d) FDA Denied Citizen Petition: Natural Variation in Carbohydrate Elements (Leading to Different Isoforms of Hormone) “Not Clinically Significant” (Similar to “No Clinically Meaningful Difference” in New Biosimilar Definition) “Sameness” Standard Satisfied when Same Primary Chemical Structure, Amino Acid Sequence, Potency, and Degree of Batch to Batch Uniformity Unusual for a Biologic
© Frommer Lawrence & Haug LLP 15 ANDA APPROVAL VEHICLE (cont’d) D.C. Circuit (upholding FDA): “Same Active Ingredient”: Chemical Identity to Extent Possible (Not Complete Identity) Isoform Variations Permissible under FDA’s “No Clinical Significance” Criterion Reasonable Interpretation under Chevron: Deference to FDA ANDA Vehicle Unlikely Now, due to Biosimilars Act
© Frommer Lawrence & Haug LLP 16 TRANSITIONAL PROVISIONS 505(b)(2) NDAs Permitted: For Biologics in Same Product Class as Biologics Previously Approved under (b)(2) Submitted Before Enactment Date (March 23, 2010), or Within 10 Years Thereafter All Biologics After Enactment Date: BLA or ABLA
© Frommer Lawrence & Haug LLP 17 TRANSITIONAL PROVISIONS (cont’d) All 505(b)(2) Approved Products: Deemed to Have Approved BLAs 10 Years after Enactment Date (Follow-On Products Then Need ABLA) Until then, 505(b)(2) Procedures Apply (including Patent Certification)
© Frommer Lawrence & Haug LLP 18 BIOSIMILAR VIA FULL BLA Full BLA Alternative Pathway NEUTROVAL (Filgrastim; Similar to Neupogen ® ) Treatment of Neutropenia (Increases White Blood Cells to Prevent Infection in Patients Undergoing Chemotherapy) Accepted by FDA (February 2010): pre- Biosimilars Act Supported by 5 Clinical Studies 780135
Copyright 2010, Morgan, Lewis & Bockius LLP Healthcare Reform--New Path for Biosimilars Kathleen M. Sanzo, Esq. Washington, DC May.
Biosimilars Where Are We Now? Where Are We Going? Sheldon Bradshaw January 24, 2008.
Copyright © 2010 by K&L Gates LLP. All rights reserved. The Biosimilars Act—A Basic Introduction Michael H. Hinckle K&L Gates Research Triangle Park, NC.
FDA Counsel.com 1 ANDAs, OTCs, Orphans and Cosmetics -- Key Issues Wednesday, August 18, 2004 SDRAN RAC STUDY COURSE Michael A. Swit, Esq. FDACounsel.com.
Development and Review Process of NDA, ANDA/AADA and OTC Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Associate Professor Department of Pharmaceutics KLE.
New York Washington Seattle Brian J. Malkin, Partner Brian J. Malkin, Partner Frommer Lawrence.
What is a Generic Medication?. The World Health Organization Definition of a Generic Medication A generic drug is a pharmaceutical product, usually intended.
© Copyright 2014 Quintiles Comparison of US/EU Biosimilar Guidelines Kamali Chance, MPH, PhD, RAC Senior Director Head, Global Biosimilars Regulatory Strategy.
Regulation of Generic Drugs Office of Generic Drugs Craig Kiester Regulatory Support Branch.
Follow-On Biologics: The New Regulatory Frontier [?] Michael S. Labson August 23, 2007.
Follow-on or Biosimilar Biologic s Points to Consider Paul Kim Foley Hoag LLP Massachusetts Biotechnology Council Thursday, May 28, 2009 © 2008 Foley Hoag.
Mary C. Till Legal Advisor Office of Patent Legal Administration Mary C. Till Legal Advisor Office of Patent Legal Administration September 8, 2010 Biotechnology.
An Abbreviated New Drug Application (ANDA) contains data which when submitted to FDA's CDER, Office of Generic Drugs, provides for the review and ultimate.
Hatch-Waxman As Amended (MMA) Thomas O. Henteleff Kleinfeld, Kaplan and Becker, LLP November 9, 2005.
What You Need to Know About Biosimilars: Products, Recent Deals, IP Issues and Licensing August 2, 2012 Madison C. Jellins 1.
Our PatientsOur PeopleOur BusinessOur Community © 2008 Endo Pharmaceuticals. All Rights Reserved. Biosimilars 2009 Update Pending Legislation Review Pam.
1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.
VALIDATION What is the new guidance?. What is a Compliance Policy Guide? Explain FDA policy on regulatory issues CGMP regulations and application commitments.
Regulation of Generic Animal Drugs in the United States VICH Outreach Forum June 25, 2014 Brussels, Belgium.
Subsequent Entry Biologics (SEBs) – Canada Presentation to AIPLA Biotechnology Committee January 25, 2012 Daphne C. Lainson
1 FDA Guidance for Industry: ANDAs: Impurities in Drug Substances Published by US FDA’s Center for Drug Evaluation and Research June 2009.
BIOSIMILARS IN THE UNITED STATES – UPDATE ON FDA IMPLEMENTATION AND OTHER CURRENT ISSUES James C. Shehan Hyman, Phelps & McNamara, P.C. 700 Thirteenth.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
WHAT IS A BIOSIMILAR? Philip D. Home, DM, DPhil Professor of Diabetes Medicine Newcastle University Consultant Diabetologist Newcastle Diabetes Centre.
Mary C. Till Senior Legal Advisor Office of Patent Legal Administration Mary C. Till Senior Legal Advisor Office of Patent Legal Administration January.
Introduction to Biosimilars Biologicals Marketing Authorization Directorate Central Administration for Pharmaceutical Affairs
Final Canadian Guidelines for “Biosimilars” Subsequent Entry Biologics (SEBs) DIA RA SIAC RD/RI Working Groups 11-May-2010 Stephen Sherman.
1 A Bayesian Non-Inferiority Approach to Evaluation of Bridging Studies Chin-Fu Hsiao, Jen-Pei Liu Division of Biostatistics and Bioinformatics National.
Patent-Extender Drugs: Loop-holes in the Law Sandy H. Yoo 4/14/06.
Quality by Design for Topical Dosage Forms Robert Lionberger Office of Generic Drugs.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
FDA’s Biosimilars Guidance -- Legal and Regulatory Considerations James S. Cohen, Esq. McDermott Will & Emery DIA Webinar April 10, 2012.
© 2009 Pharmaceutical Law Group PC Market Exclusivity Paradigm Gregory J. Glover, MD, JD Pharmaceutical Law Group
1 Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview Lawrence X. Yu, Ph.D. Director for Science Office of Generic Drugs, OPS, CDER Food.
1 CRC Orientation Prerequisite January 2008 Investigational New Drug Application (IND)
Addressing Biosimilars: Federal Legislation for a Pathway May 28, 2009 Kerry A. Flynn Shire Human Genetic Therapies, Inc.
CHALLENGES FACED IN THE DEVELOPMENT OF BIOSIMILARS Dr.G.Hima Bindu MD; PG dip. diabetology Asst.Professor Dept. of Pharmacology Rajiv Gandhi Institute.
1 Advisory Committee for Pharmaceutical Science May 4, 2005 Using Product Development Information to Address the Bioequivalence Challenges of Highly-variable.
Hogan & Hartson L.L.P. Regulatory and Legal Challenges for Developers of Drug Delivery Devices Public Workshop: Innovative Systems for Delivery of Drugs.
AXINN, VELTROP & HARKRIDER LLP © 2007 | AXINN, VELTROP & HARKRIDER LLP Click To Modify Title Name Goes Here FDA Hearings on the BPCI Act.
© 2008 Dechert LLP Pharma v. Pharma or Pharma & Pharma: The Legal Interface Between the Makers of Original and Copied Versions of Medicines AIPLA Antitrust,
A New Pathway for Follow-on Biologics Presented by: Steve Nash May 7, 2010.
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
History of Pediatric Labeling Steven Hirschfeld, MD PhD CDR USPHS Division of Oncology Drug Products & Division of Pediatric Drug Development, CDER, FDA.
Special Topics in IND Regulation David Roeder, M.S. Associate Director for Regulatory Affairs Office of Drug Evaluation IV Center for Drugs, FDA April.
Investigational New Drug Application 21 CFR Part 312 A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International
Processing and Product Quality Issues Keith Wonnacott Ph.D. Office of Cellular, Tissue, and Gene Therapies E BC R Moving from Investigational to Licensed.
1 Combination Products: Jurisdictional Issues MassMEDIC Presentation March 28, 2006 Janice Hogan, Esq. Partner Hogan & Hartson, LLP
SNM June Overview of FDA's Regulatory Framework for PET Drugs Ravindra K. Kasliwal, Ph.D. Office of New Drug Quality Assessment Center for Drug Evaluation.
© 2017 SlidePlayer.com Inc. All rights reserved.